Thrombolysis for acute myocardial infarction

Circulation

Volumn 97, Issue 16, 1998, Pages 1632-1646

  White, Harvey D ^a,b   Van de Werf, Frans J J ^a,b  

^a GREEN LANE HOSPITAL   (New Zealand)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Myocardial infarction; Plasminogen activators; Streptokinase; Thrombolysis

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032574630     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.16.1632     Document Type: Article

References (127)

1. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA. 1912;59:2015-2020.
2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engt J Med. 1980;303: 897-902.
3. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 1958;71: 287-296.
4. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985;6:556-585.
5. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. Intracoronary administration of fibrinolysin in acute myocardial infarct. Ter Arkh. 1976;48:8-19.
6. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Köstering H, Oster H, Leitz K. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cordiol. 1979;2:354-363.
7. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A. Califf RM, Ross AM, for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923-1928.
8. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 1987; 76:142-154.
9. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction [published erratum appears in N Engl J Med. 1994;330:516]. N Engl J Med. 1993;329:1615-1622.
10. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990;82:781-791.
11. Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993;87:1792-1805.
12. Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, van der Pol JMJ, van Eenige MJ. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographie study: results of the APRICOT Study. Circulation. 1993;87:1524-1530.
13. White HD, French JK, Hamer AW, Brown MA, Williams BF, Ormiston JA, Cross DB. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol. 1995;25:218-223.
14. White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation. 1994;89:61-67.
15. Lamas GA, Flaker GC, Mitchell G, Smith SC Jr, Gersh BJ, Wun CC, Moye L, Rouleau JL, Rutherford JD, Pfeffer MA, Braunwald E, for the Survival and Ventricular Enlargement Investigators. Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation. 1995;92:1101-1109.
16. Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction: a 12-month follow- up report. N Engl J Med. 1985;312:1073-1078.
17. Simoons ML, Serruys PW, van den Brand M, Bär F, de Zwaan C, Res J, Verheugt FWA, Krauss XH, Remme WJ, Vermeer F, Lubsen J. Improved survival after early thrombolysis in acute myocardial infarction: a randomised trial by the Interuniversity Cardiology Institute in the Netherlands. Lancet. 1985;2:578-582.
18. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
19. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med. 1986;314:1465-1471.
20. Van de Werf F, Arnold AER, for the European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. Intravenous tissue plasminogen activator and size of infarct. left ventricular function, and survival in acute myocardial infarction. BMJ. 1988;297:1374-1379.
21. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
22. Wilcox RG, von der Lippe G, Ollson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activation for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
23. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
24. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987;317:850-855.
25. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Norris RM. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med. 1989;320:817-821.
26. Rossi P, Bolognese L, on behalf of Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol. 1991;68:585-592.
27. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
28. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 1993;342:767-772.
29. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
30. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) Study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet. 1993;342:759-766.
31. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
32. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, Ellis CJ, Williams MG, White HD. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ. 1996;312: 1637-1641.
33. The International Study Group. In-hospital mórtality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
34. Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilator therapy. N Engl J Med. 1987;317:1055-1059.
35. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave-front phenomenon of ischemic cell death, I: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
36. Yellon DM, Hearse DJ, Crome R, Wyse RKH. Temporal and spatial characteristics of evolving cell injury during regional myocardial ischemia in the dog: the 'border zone' controversy. J Am Coll Cardiol. 1983;2:661-670.
37. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F. Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation. 1995;91:291-297.
38. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343: 311-322.
39. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771-775.
40. Newby KL, Rutsch WR, Califf RM, Simoons ML, Aylward PE, Armstrong PW, Woodlief LH, Lee KL, Topol EJ, Van de Werf F, for the GUSTO-I Investigators. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol. 1996;27:1646-1655.
41. Herlitz J, Hartford M, Blohm M, Karlson BW, Ekstrom L, Risenfors M, Wennerblom B, Luepker RV, Holmberg S. Effect of a media campaign on delay times and ambulance use in suspected acute myocardial infarction. Am J Cardiol. 1989;64:90-93.
42. Cerqueira MD, Maynard C, Ritchie JL, Davis KB, Kennedy JW. Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction Trials. J Am Coll Cardiol. 1992;20:1452-1459.
43. Topol EJ, Califf RM, George BS, and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
44. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol. 1990;16:249-292.
45. Roig E, Castaner A, Simmons B, Patel R, Ford E, Cooper R. In-hospital mortality rates from acute myocardial infarction by race in U.S. hospitals: findings from the National Hospital Discharge Survey. Circulation. 1987;76:280-288.
46. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2) and The International Study Group. N Engl J Med. 1992;327:1-6.
47. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
48. Katz A, Cohn G, Mashal A, Cristal N. Thrombolytic therapy for acute myocardial infarction in a 110-year-old man. Am J Cardiol. 1993;71: 1122-1123.
49. White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ, for the GUSTO-I Investigators. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I Trial. Circulation. 1996;94:1826-1833.
50. Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, Eisenberg MS, Ho MT, Cobb LA, Kennedy JW, Wirkus MS, the MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cordiol. 1991;18:657-662.
51. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison M, Tiefenbrunn AJ, Weaver WD, for the Participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90: 2103-2114.
52. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G. White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr, Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.
53. Mauri F, Gasparini M, Barbonaglia L, Santoro E, Franzosi MG, Tognoni G, Rovelli F. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol. 1989;63:1291-1295.
54. Berger PB, Ryan T. Inferior myocardial infarction: high-risk subgroups. Circulation. 1990;81:401-411.
55. Zehender M, Kasper W, Kauder E, Schonthaler M, Geibel A, Olschewski M, Just H. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med. 1993;328:981-988.
56. White HD. Should all occluded infarct-related arteries be opened? Eur Heart J. 1997;18:1207-1209.
57. Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS, GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med. 1996;334:481-487.
58. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
59. de Jaegere PP, Arnold AA, Balk AH, Simoons ML. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol. 1992;19:289-294.
60. Granger C, White H, Simoons M, Weaver D, Gore J, Aylward P, Barbash G, Lee K, Califf R, GUSTO Investigators. Risk factors for stroke following thrombolytic therapy: case-control study from the GUSTO trial. J Am Coll Cardiol. 1995;25:232A. Abstract.
61. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topol EJ, Ross AM, for the GUSTO-I Angiographic Investigators. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol. 1996;28:1661-1669.
62. Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, Topol EJ, for the GUSTO-I Investigators. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction: a randomized trial. Ann Intern Med. 1996;125:891-900.
63. Elliott JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol. 1993;71:640-645.
64. White H. Thrombolytic treatment for recurrent myocardial infarction. BMJ. 1991;302:429-430.
65. Cross DB, White HD. Allergic reactions to streptokinase: does antibody formation prevent reuse in a second myocardial infarction? Clin Immunother. 1994;2:415-420.
66. Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM, for the GUSTO-I Investigators. Treating menstruating women with thrombolytic therapy: insights from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. J Am Coll Cardiol. 1995;26:1651-1656.
67. Doorey AJ, Michelson EL, Topol EJ. Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises. JAMA. 1992; 268:3108-3114.
68. Neches RB, Goldfarb AM. Thrombolytic therapy after cardiopulmonary resuscitation in acute myocardial infarction. Am J Cardiol. 1993;71:258.
69. Scholz KH, Tebbe U, Hermann C, Wojcik J, Lingen R, Chemnitius JM, Brune S, Kreuzer H. Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarction. Am J Cardiol. 1992;69:724-728.
70. Weston CFM, Avery P. Thrombolysis following pre-hospital cardiopulmonary resuscitation. Int J Cardiol. 1992;37:195-198.
71. American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. ACC/AHA Guidelines for the early management of patients with acute myocardial infarction. Circulation. 1990;82:664-707.
72. Barbash GI, White HD, Modan M, Van de Werf F, Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993;22: 707-713.
73. Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM, for the GUSTO-I Investigators. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol. 1997; 30:1606-1610.
74. Cahane M, Ashkenazi I, Avni I, Blumenthal M. Total hyphema following streptokinase administration eight days after cataract extraction. Br J Ophthalmol. 1990;74:447. Letter.
75. Sunderraj P. Intraocular hemorrhage associated with intravenously administered streptokinase. Am J Ophthalmol. 1991;112:734-735. Letter.
76. Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina: relation to timing of angiography and in-hospital cardiac events. Circulation. 1989; 80:17-23.
77. Lee HS, Cross SJ, Rawles JM, Jennings KP. Patients with suspected myocardial infarction who present with ST depression. Lancet. 1993; 342:1204-1207.
78. Langer A, Goodman SG, Topol EJ, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW, for the LATE Study Investigators. Late Assessment of Thrombolytic Efficacy (LATE) Study: prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol. 1996;27:1327-1332.
79. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
80. Prewitt RM, Gu S, Shick U, Ducos J. Intraaortic balloon counterpulsation enhances coronary thrombolysis. J Am Coll Cardiol. 1994;23: 794-798.
81. Zahger D, Cercek B, Cannon CP, Jordan M, Shah PK, for the TIMI-4 Investigators. Thrombolytic therapy for acute myocardial infarction in patients with prior coronary bypass surgery: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial. J Thromb Thrombolys. 1995;2:45-50.
82. DeFranco AC, Abramouritz B, Kirchbaum D, Topol EJ. Substantial (threefold) benefit of accelerated t-PA over standard thrombolytic therapy in patients with prior bypass surgery and acute MI: results of GUSTO Trial, J Am Coll Cardiol. 1994;23:345A. Abstract.
83. Castaigne AD, Hervé C, Duval-Moulin A-M, Gaillard M, Dubois-Rande J-L, Boesch C, Wolf M, Lellouche D, Jan F, Vernant P, Huguenard P. Prehospital use of APSAC: results of a placebo-controlled study. Am J Cardiol. 1989;64:30A-33A.
84. McNeill AJ, Cunningham SR, Flannery DJ, Dalzell GWN, Wilson CM, Campbell NPS, Khan MM, Patterson GC, Webb SW, Adgey AAJ. A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. Br Heart J. 1989:61:316-321.
85. Barbash GI, Roth A, Hod H, Miller HI, Modan M, Rath S, Zahav YH, Shachar A, Basan S, Battler A, Rabinowitz B, Kaplinsky E, Seligsohn U, Laniado S. Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:261-266.
86. Schofer J, Büttner J, Geng G, Gutschmidt K, Herden HN, Mathey DG, Moecke HP, Polster P, Raftopoulo A, Sheehan FH, Voelz P. Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol. 1990;66:1429-1433.
87. The GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian Region Early Anistreplase Trial. BMJ. 1992;305:548-553.
88. McAleer B, Ruane B, Burke E, Cathcart M, Costello A, Dalton G, Williams JR, Varma MPS. Prehospital thrombolysis in a rural community: short- and long-term survival. Cardiovasc Drugs Ther. 1992;6:369-372.
89. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med. 1993;329:383-389.
90. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M, for the Myocardial Infarction Triage, and Intervention Trial. Prehospital-initiated vs hospital-initiated thrombolytic therapy. JAMA. 1993;270:1211-1216.
91. Gallagher D, O'Rourke M, Healey J, Hillman K, McLean A, Hall J, Graham K, Hawkins J. Paramedic-initiated, prehospital thrombolysis using urokinase in acute coronary occlusion (TICO 2). Coron Artery Dis. 1992;3:605-609.
92. Weaver WD. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. J Am Coll Cardiol. 1995;25(suppl 7):3S-9S.
93. White HD. Thrombolytic therapy for patients with myocardial infarction presenting after six hours. Lancet. 1992;340:221-222.
94. Califf RM, Woodlief LH, Harrell FE Jr, Lee KL, White HD, Guerci A, Barbash GI, Simes RJ, Weaver WDD, Simoons ML, Topol EJ, for the GUSTO-I Investigators. Selection of thrombolytic therapy for individual patients: development of a clinical model. Am Heart J. 1997;133:630-639.
95. White HD. GISSI-2 and the heparin controversy. Lancet. 1990;336: 297-298.
96. Wall TC, Califf RM, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ. Accelerated plasminogen activator dose regimens for coronary thrombolysis: the TAMI-7 Study Group. J Am Coll Cardiol. 1992;19:482-489.
97. Woo KS, White HD. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Pharmacoeconomics. 1993;3:192-204.
98. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL, Clapp-Channing NE, Sutherland W, Pilote L, Armstrong PW. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med. 1994;331:1130-1135.
99. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation. 1989;79:441-444.
100. White HD. Mechanism of late benefit in ISIS-2. Lancet. 1988;2: 914-914. Letter.
101. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation. 1995;91: 2862-2864.
102. Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K, Masuyama T. Kitabatake A, Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992;85:1699-1705.
103. Maes A, Mortelmans L, Nuyts JM, Verbruggen AM, Van de Werf F. Myocardial tissue perfusion measured with PET in patients with TIMI flow grade 3 after thrombolysis. Circulation. 1994;90(suppl I):I-220. Abstract.
104. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI Study. Lancet. 1987;2:871-874.
105. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS Study. Lancet. 1990;335:427-431.
106. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET Study. Lancet. 1990;335:1175-1178.
107. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, on behalf of the ISIS-2 Collaborative Group. ISIS-2: 10-year survival in a randomised comparison of intravenous streptokinase, oral aspirin, both, or neither among patients with suspected acute myocardial infarction. Br Med J. In press.
108. Van de Werf F. Discrepancies between the effects of coronary reperfusion on left ventricular function and survival. Lancet. 1989;1:1367-1369.
109. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
110. Elliott JM, Williams BF, White HD. Streptokinase and lifestyle outcome in survivors of myocardial infarction. N Z Med J. 1992;105:163-164.
111. Lijnen HR, Collen D. Experimental studies in thrombolysis and fibrinolysis. Curr Opin Cardiol. 1993;8:613-620.
112. Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science. 1989;243:51-56.
113. Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, and the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995;91:2725-2732.
114. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, Chernoff R, Christie LG, Feldman RL, Seals AA, Weaver WD. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891-898.
115. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence [published erratum appears in Lancet. 1995;346:980]. Lancet. 1995;346:329-336.
116. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etchevery T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670-3674.
117. Cannon CP, McCabe CH, Gibson MC, Adgey JA, Sweiger MJ, Sequeira RF, Muller HS, McCluskey ER, Fox NL, Van de Werf F, Braunwald E. TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial. Circulation. 1997;96(suppl I):I-206. Abstract.
118. Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem. 1991;266:8156-8161.
119. de Munk GAW, Ryken DC. Fibrinolytic properties of single-chain urokinase-type plasminogen activator (pro-urokinase). Fibrinolysis. 1990;4:1-9.
120. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against Streptokinase in acute myocardial infarction. Lancet. 1989;1:863-868.
121. Bär FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spiecker M, Macaya C, Hanssen M, Heras M, Boland JP, Morice MC, Dunn FG, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen AJ, Klein W, Windeler J, Hopkins G, Barth H, von Fisenne MJM. Comparison of saruplase and alteplase in acute myocardial infarction: the Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol. 1997;79:727-732.
122. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins G, Fennell W, Betriu A, Ruda M, Mlczoch J. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol. 1998;31:487-493.
123. Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood. 1994;84:680-686.
124. Vanderschueren S, Barrios L, Kerdsinchai P, van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F, for the STAR Trial Group. A randomized trial of recombinant Staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation. 1995;92:2044-2049.
125. Vanderschueren S, Dens J, Kerdsinchai P, Desmet W, Vrolix M, De Man F, van den Heuvel P, Hermans L, Collen D, Van de Werf F. Randomized coronary patency trial of double-bolus recombinant Staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J. 1997;134:213-219.
126. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2×2 tables. Biometrics. 1977;33:593-602.
127. White HD. Thrombolytic therapy and equivalence trials. J Am Coll Cardiol. In press.